In a research report released Friday, H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on shares of Agenus Inc. (NASDAQ:AGEN), with a price target of $10, after the company reported second-quarter financials and provided ...
Agenus logo Agenus Inc. (NASDAQ:AGEN) released its quarterly earnings results on Thursday. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.34) by $0.01.
What: Shares of Agenus (NASDAQ:AGEN), a small-cap biopharmaceutical company intent on unleashing patients' own immune systems to fight cancer, rocketed 43% higher in March, according to data from S&P Global Market Intelligence.
This is a fundamental star rating report for Agenus Inc. (NasdaqCM:AGEN) . The Capital Market Laboratories Star Rating is an objective, quantifiable measure of a company's operating and financial condition.